KR20210096612A - IgA 항체 구축물을 포함하는 조성물 및 방법 - Google Patents
IgA 항체 구축물을 포함하는 조성물 및 방법 Download PDFInfo
- Publication number
- KR20210096612A KR20210096612A KR1020217016137A KR20217016137A KR20210096612A KR 20210096612 A KR20210096612 A KR 20210096612A KR 1020217016137 A KR1020217016137 A KR 1020217016137A KR 20217016137 A KR20217016137 A KR 20217016137A KR 20210096612 A KR20210096612 A KR 20210096612A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody construct
- heavy chain
- domain
- amino acid
- iga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203183 | 2018-10-29 | ||
| EP18203183.1 | 2018-10-29 | ||
| US201862752641P | 2018-10-30 | 2018-10-30 | |
| US62/752,641 | 2018-10-30 | ||
| PCT/US2019/058648 WO2020092427A1 (en) | 2018-10-29 | 2019-10-29 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210096612A true KR20210096612A (ko) | 2021-08-05 |
Family
ID=70462698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217016137A Ceased KR20210096612A (ko) | 2018-10-29 | 2019-10-29 | IgA 항체 구축물을 포함하는 조성물 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210332131A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873942A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022506761A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210096612A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113260632A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019369397B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3118312A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2596411B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092427A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3131705A1 (en) * | 2019-03-27 | 2020-10-01 | Umc Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
| CA3187850A1 (en) | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| JP2023546679A (ja) * | 2020-10-22 | 2023-11-07 | アクティニウム ファーマシューティカルズ インコーポレイテッド | がん治療における放射免疫療法とcd47遮断の併用 |
| CN116829698A (zh) * | 2020-12-07 | 2023-09-29 | 加利福尼亚大学董事会 | 通过SIRP-α衔接体的先天免疫细胞沉默 |
| CN116731161A (zh) * | 2021-09-18 | 2023-09-12 | 南开大学 | 工程化IgG和IgA嵌合的“四叶草型X抗体” |
| EP4475886A4 (en) * | 2022-02-09 | 2026-03-18 | Exelixis Inc | MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226878D0 (en) * | 2002-11-18 | 2002-12-24 | Univ Warwick | Antibodies |
| HUE038955T2 (hu) * | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US10407513B2 (en) * | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| WO2013087914A1 (en) * | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
| RU2693078C2 (ru) * | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| US20140213771A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Multi-specific binding proteins |
| EP2970485A1 (en) * | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3188758B1 (en) * | 2014-08-08 | 2023-10-04 | The Board of Trustees of the Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| ES2751915T5 (es) * | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
| US9650441B2 (en) * | 2015-09-21 | 2017-05-16 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| CA3035427A1 (en) * | 2016-09-01 | 2018-03-08 | Umc Utrecht Holding B.V. | Cd20 antibodies |
| KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
| WO2019022600A1 (en) * | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47 |
| AU2018314765C1 (en) * | 2017-08-08 | 2025-11-20 | Bruker Spatial Biology, Inc. | Obinutuzumab treatment of a DLBCL patient subgroup |
-
2019
- 2019-10-29 GB GB2107478.6A patent/GB2596411B/en active Active
- 2019-10-29 EP EP19879444.8A patent/EP3873942A4/en active Pending
- 2019-10-29 AU AU2019369397A patent/AU2019369397B2/en active Active
- 2019-10-29 CN CN201980087109.4A patent/CN113260632A/zh active Pending
- 2019-10-29 JP JP2021524345A patent/JP2022506761A/ja active Pending
- 2019-10-29 WO PCT/US2019/058648 patent/WO2020092427A1/en not_active Ceased
- 2019-10-29 CA CA3118312A patent/CA3118312A1/en active Pending
- 2019-10-29 KR KR1020217016137A patent/KR20210096612A/ko not_active Ceased
-
2021
- 2021-04-28 US US17/242,793 patent/US20210332131A1/en active Pending
-
2024
- 2024-08-26 JP JP2024144789A patent/JP2024170456A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2596411B (en) | 2023-09-20 |
| CA3118312A1 (en) | 2020-05-07 |
| EP3873942A4 (en) | 2022-12-28 |
| GB202107478D0 (en) | 2021-07-07 |
| JP2022506761A (ja) | 2022-01-17 |
| EP3873942A1 (en) | 2021-09-08 |
| AU2019369397A1 (en) | 2021-05-27 |
| US20210332131A1 (en) | 2021-10-28 |
| GB2596411A (en) | 2021-12-29 |
| WO2020092427A1 (en) | 2020-05-07 |
| AU2019369397B2 (en) | 2026-07-23 |
| JP2024170456A (ja) | 2024-12-10 |
| CN113260632A (zh) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112513085B (zh) | Psma结合剂及其用途 | |
| CA2599734C (en) | Humanized l243 antibodies | |
| US20210332131A1 (en) | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS | |
| US12258420B2 (en) | Engineered IGA antibodies and methods of use | |
| KR102885855B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
| TW201600527A (zh) | 結合人類大麻素1(cb1)受體之抗體 | |
| TWI784932B (zh) | 結合人類大麻素1(cb1)受體之抗體 | |
| WO2021008523A1 (zh) | 抗tigit抗体及其应用 | |
| AU2022214491A1 (en) | Psma binding proteins and uses thereof | |
| RU2770620C1 (ru) | Связывающие молекулы, вызывающие клеточную активацию | |
| JP2023536631A (ja) | 多重特異性結合性作用剤およびその使用 | |
| TW202237187A (zh) | 組合療法 | |
| JP2025539455A (ja) | 抗tfr1抗体及びその使用 | |
| CN115698066A (zh) | 抗cd47抗体及其用途 | |
| HK40059443A (en) | Compositions and methods comprising iga antibody constructs | |
| JP7789368B2 (ja) | 炎症性腸疾患に対する治療用抗体 | |
| CN117580867A (zh) | Psma结合蛋白及其用途 | |
| TW202517683A (zh) | 可活化之ror結合劑及其用途 | |
| HK40067884A (en) | Engineered iga antibodies and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |